Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KLS-1 in Malignant Neoplasms
NCT06506643Phase 2Recruiting
- Sponsor
- Vector Vitale
- Start
- May 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zinc aspartate in solid tumor, chronic lymphocytic leukemia (CLL), melanoma and 2 more (6 arms), sponsored by Vector Vitale. Primary endpoints: Dose Limiting Toxicities, Treatment Emergent Adverse Events and 2 more. Started May 2024; status: recruiting.
02
Drugs
zinc aspartate
03
Conditions
solid tumorchronic lymphocytic leukemia (CLL)melanomaprostate cancer (PCa)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06506643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06506643.